ProShare Advisors’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.4M Sell
34,560
-1,435
-4% -$532K 0.02% 329
2026
Q1
$10.5M Sell
35,995
-7,162
-17% -$2.35M 0.02% 349
2025
Q4
$15.1M Buy
43,157
+904
+2% +$305K 0.03% 301
2025
Q3
$13.7M Buy
42,253
+2,025
+5% +$630K 0.03% 312
2025
Q2
$15.6M Buy
40,228
+3,455
+9% +$1.39M 0.03% 295
2025
Q1
$16M Buy
36,773
+1,670
+5% +$670K 0.04% 282
2024
Q4
$12.9M Buy
35,103
+3,828
+12% +$1.6M 0.03% 293
2024
Q3
$16.3M Sell
31,275
-2,514
-7% -$1.34M 0.04% 272
2024
Q2
$18.3M Sell
33,789
-692
-2% -$366K 0.05% 253
2024
Q1
$17.9M Sell
34,481
-851
-2% -$423K 0.05% 253
2023
Q4
$16.7M Sell
35,332
-3,926
-10% -$1.82M 0.05% 252
2023
Q3
$17.1M Sell
39,258
-2,530
-6% -$1.15M 0.05% 247
2023
Q2
$18.6M Buy
41,788
+191
+0.5% +$88.1K 0.05% 247
2023
Q1
$19.1M Buy
41,597
+8,654
+26% +$4.12M 0.06% 243
2022
Q4
$16.9M Sell
32,943
-294
-0.9% -$149K 0.06% 234
2022
Q3
$15.1M Sell
33,237
-3,918
-11% -$1.87M 0.06% 241
2022
Q2
$17.9M Sell
37,155
-14,782
-28% -$7.31M 0.06% 245
2022
Q1
$25.5M Sell
51,937
-1,451
-3% -$663K 0.05% 220
2021
Q4
$24.7M Buy
53,388
+11,677
+28% +$4.91M 0.05% 218
2021
Q3
$15.6M Sell
41,711
-1,159
-3% -$440K 0.04% 286
2021
Q2
$16.4M Buy
42,870
+6,902
+19% +$2.64M 0.05% 280
2021
Q1
$12.9M Sell
35,968
-34
-0.1% -$10.9K 0.04% 309
2020
Q4
$11.6M Buy
36,002
+2,974
+9% +$913K 0.04% 282
2020
Q3
$8.87M Buy
33,028
+2,745
+9% +$739K 0.04% 280
2020
Q2
$7.96M Buy
30,283
+3,881
+15% +$1.04M 0.04% 286
2020
Q1
$5.99M Sell
26,402
-18,172
-41% -$4.95M 0.04% 323
2019
Q4
$13.5M Buy
44,574
+8,812
+25% +$2.42M 0.06% 274
2019
Q3
$8.59M Buy
35,762
+1,898
+6% +$520K 0.05% 340
2019
Q2
$9.56M Sell
33,864
-7,565
-18% -$2.07M 0.06% 312
2019
Q1
$11.9M Buy
41,429
+1,743
+4% +$504K 0.07% 228
2018
Q4
$10.4M Sell
39,686
-4,853
-11% -$1.33M 0.07% 210
2018
Q3
$12.2M Sell
44,539
-4,531
-9% -$1.18M 0.08% 187
2018
Q2
$11.7M Sell
49,070
-2,324
-5% -$538K 0.08% 199
2018
Q1
$11.3M Buy
51,394
+1,433
+3% +$337K 0.07% 212
2017
Q4
$11.2M Buy
49,961
+8,033
+19% +$1.71M 0.08% 215
2017
Q3
$7.96M Buy
41,928
+918
+2% +$175K 0.07% 265
2017
Q2
$7.71M Sell
41,010
-312
-0.8% -$56.1K 0.08% 245
2017
Q1
$6.83M Buy
41,322
+266
+0.6% +$42.3K 0.07% 278
2016
Q4
$5.9M Buy
41,056
+8,624
+27% +$1.15M 0.07% 299
2016
Q3
$4.06M Sell
32,432
-10,640
-25% -$1.37M 0.06% 278
2016
Q2
$5.66M Buy
43,072
+484
+1% +$66.2K 0.07% 214
2016
Q1
$5.92M Sell
42,588
-17,976
-30% -$2.4M 0.08% 217
2015
Q4
$8.45M Buy
60,564
+15,047
+33% +$2.07M 0.1% 194
2015
Q3
$6.37M Buy
45,517
+1,249
+3% +$188K 0.09% 232
2015
Q2
$7.27M Sell
44,268
-7,613
-15% -$1.22M 0.1% 208
2015
Q1
$8.01M Sell
51,881
-16,108
-24% -$2.29M 0.09% 217
2014
Q4
$8.54M Buy
67,989
+4,920
+8% +$608K 0.1% 217
2014
Q3
$7.54M Sell
63,069
-3,460
-5% -$397K 0.1% 194
2014
Q2
$7.16M Sell
66,529
-5,658
-8% -$583K 0.09% 202
2014
Q1
$7.19M Buy
72,187
+1,160
+2% +$105K 0.09% 192
2013
Q4
$6.56M Buy
71,027
+26,040
+58% +$2.31M 0.1% 208
2013
Q3
$3.76M Sell
44,987
-13,637
-23% -$1.17M 0.09% 181
2013
Q2
$4.8M Buy
+58,624
New +$4.39M 0.09% 194

Other funds holding ELV

ProShare Advisors's ELV Position: Q2 2026 in Review

ProShare Advisors reduced its Elevance Health (ELV) stake by 4% in Q2 2026, selling an estimated $532K and leaving 34,560 shares worth $13.4M. The position accounts for 0.02% of the portfolio, ranked #329.

ProShare Advisors first reported a position in ELV in Q2 2013 and has held it in 53 quarters since. The position peaked at $25.5M in Q1 2022. 1,602 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • ProShare Advisors held 34,560 shares of Elevance Health worth $13.4M as of Q2 2026.
  • ProShare Advisors sold 1,435 Elevance Health shares in Q2 2026, an estimated $532K.
  • Elevance Health made up 0.02% of ProShare Advisors's portfolio in Q2 2026, its #329 holding.
  • ProShare Advisors first reported a position in Elevance Health in Q2 2013 and has held it in 53 quarters since.
  • ProShare Advisors's Elevance Health position peaked at $25.5M in Q1 2022.
  • 1,602 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.